FDA Advisory Committee Does Not Recommend Approval of Inhalant Linhaliq
Bronchiectasis
The Antimicrobial Drugs Advisory Committee (ADAC) of the U.S. Food and Drug Administration (FDA) did not recommend approval of Aradigm’s Linhaliq for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients ... Read more